85 related articles for article (PubMed ID: 23242444)
1. Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation.
van Geffen WH; Hiltermann TJ; Groen HJ
J Thorac Oncol; 2013 Jan; 8(1):e1-2. PubMed ID: 23242444
[No Abstract] [Full Text] [Related]
2. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
[No Abstract] [Full Text] [Related]
3. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Choi YL; Soda M; Yamashita Y; Ueno T; Takashima J; Nakajima T; Yatabe Y; Takeuchi K; Hamada T; Haruta H; Ishikawa Y; Kimura H; Mitsudomi T; Tanio Y; Mano H;
N Engl J Med; 2010 Oct; 363(18):1734-9. PubMed ID: 20979473
[TBL] [Abstract][Full Text] [Related]
4. A patient with complex multiple genomic ALK alterations.
Liu X; Rice SJ; Jamis-Dow CA; Abendroth C; Ali S; Almokadem S; Belani CP
Thorax; 2016 Apr; 71(4):383-5. PubMed ID: 26839360
[No Abstract] [Full Text] [Related]
5. Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.
Toyokawa G; Takenoyama M; Watanabe S; Toyozawa R; Inamasu E; Kojo M; Shiraishi Y; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Ichinose Y
J Thorac Oncol; 2013 Nov; 8(11):e96-8. PubMed ID: 24128725
[No Abstract] [Full Text] [Related]
6. Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.
Saber A; van der Wekken AJ; Kok K; Terpstra MM; Bosman LJ; Mastik MF; Timens W; Schuuring E; Hiltermann TJ; Groen HJ; van den Berg A
PLoS One; 2016; 11(4):e0153065. PubMed ID: 27045755
[TBL] [Abstract][Full Text] [Related]
7. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC
J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446
[No Abstract] [Full Text] [Related]
8. More on crizotinib.
Shen L; Ji HF
N Engl J Med; 2011 Feb; 364(8):777-8. PubMed ID: 21345111
[No Abstract] [Full Text] [Related]
9. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
[TBL] [Abstract][Full Text] [Related]
10. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
[No Abstract] [Full Text] [Related]
11. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations in a patient with ALK-rearranged lung cancer.
Giri S; Patel JK; Mahadevan D
N Engl J Med; 2014 Oct; 371(17):1655-6. PubMed ID: 25337766
[No Abstract] [Full Text] [Related]
13. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
Perez CA; Velez M; Raez LE; Santos ES
Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
[TBL] [Abstract][Full Text] [Related]
14. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.
Maillet D; Martel-Lafay I; Arpin D; Pérol M
J Thorac Oncol; 2013 Apr; 8(4):e30-1. PubMed ID: 23486270
[No Abstract] [Full Text] [Related]
15. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
Costa DB; Kobayashi S
J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
[No Abstract] [Full Text] [Related]
16. Clinical response to crizotinib retreatment after acquisition of drug resistance.
Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
[No Abstract] [Full Text] [Related]
17. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Kaneda H; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
[No Abstract] [Full Text] [Related]
18. Crizotinib--latest champion in the cancer wars?
Hallberg B; Palmer RH
N Engl J Med; 2010 Oct; 363(18):1760-2. PubMed ID: 20979477
[No Abstract] [Full Text] [Related]
19. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.
Kim YH; Ozasa H; Nagai H; Sakamori Y; Yoshida H; Yagi Y; Nakaoku T; Mishima M
J Thorac Oncol; 2013 Sep; 8(9):e85-6. PubMed ID: 23945393
[No Abstract] [Full Text] [Related]
20. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
Browning ET; Weickhardt AJ; Camidge DR
J Thorac Oncol; 2013 Mar; 8(3):e21. PubMed ID: 23407562
[No Abstract] [Full Text] [Related]
[Next] [New Search]
